Technology

Swift Biosciences, a leading company of innovative library prep remedies for genomic sequencing, today revealed the launch of Accel-NGS 2S Indexed Adapters, a new portfolio of indices that substantially improves multiplexed next-generation sequencing on Illumina platforms. This unique set of indices offers the biggest set of commercially available, single indices for high-throughput genomic sequencing applications, making it possible for users to dependably complex as much as 96 single-indexed samples and 768 dual-indexed examples each run. This industry-leading technology satisfies the expanding demand from research and core research laboratories to merge higher example numbers each instrument run, enabling even more affordable sequencing while supplying far better data accuracy.

Multiplex DNA sequencing is an usual workflow where multiple samples are classified and merged together into a solitary run to raise throughput and to reduce sequencing price per sample. Current peer-reviewed publications have actually shown other commercially offered indices are affected by multiplexing errors, called "index hopping" - the misassignment of sequencing reads to the wrong example. In addition, older movie theater DNA sequencing modern technologies are prone to other sequencing mistakes, intensifying the misassignment error prices. As sequencing systems enhance capability, such as Illumina's newest platform, NovaSeq , the need for high rigid indices to make it possible for multitudes of examples to be multiplexed remains in huge need.

Researchers at Swift Biosciences claimed its Accel-NGS 2S Indexed Adapters are a collection of 96 solitary indices enhanced to work in mix with Illumina TruSeq P5 adapters to offer up to 768 unique dual-index mixes. These new indices are maximized to offer higher flexibility to process between 96-768 uniquely marked samples each run and could accommodate a wider range of tasks with differing sequencing deepness. In addition, the unique design removes misassignment and index hopping, a concern certain to Illumina's pattern flow cells. These enhancements give higher sensitivity to spot radio frequency versions along with greater fidelity to accelerate de-multiplexing during data analysis.

" Our goal at Swift is to make it possible for scientists to produce the finest information from any type of sample kind, letting them push the boundaries of their scientific research," specified Timothy Harkins, president and CEO of Swift Biosciences. "Our new Accel-NGS 2S Indexed Adapters close the throughput and price void on Illumina systems, and when combined with Accel-NGS FEW modern technologies, all types of sequencing labs are generating higher quality information in a lot more affordable manner."

First Commercial Order

The new Accel-NGS 2S Indexed Adapters are commercially readily available currently. The very first industrial order delivered to Shanghai Nanodigmbio Biotechnology Co. LTD, a distribution network partner for Swift's product portfolio in China. Shanghai Nanodigmbio Biotechnology is one of the fastest growing sequencing markets and an essential gamer in genomics and condition study. In 2016, China unveiled its "Five-Year Plan" with a tactical focus on precision medicine, a quickly expanding focal location of genomics that will certainly direct future diagnostic and therapeutic growth.

" Swift's new indexed adapters offer a significant benefit to scientists conducting target enrichment sequencing," claimed Opportunity Wu, CEO of Shanghai Nanodigmbio Biotechnology Company. "Currently it will be possible for researchers to make the most of the variety of exomes each run to rapidly survey bigger sample sets in an extra cost-efficient manner.

• Tags
• #Business
• #Magazine
• #Lifestyle